protocolSection identificationModule nctId: NCT06289829, orgStudyIdInfo id: 4-2023-1605, briefTitle: The Appropriate Remifentanil Dose for Optimal Insertion of Laryngeal Mask Airway in Adult Patients During Induction of General Anesthesia Using Remimazolam., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-02, primaryCompletionDateStruct date: 2025-07-29, completionDateStruct date: 2025-07-29, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Yonsei University, class: OTHER, descriptionModule briefSummary: The laryngeal mask airway (LMA) is an airway maintenance device that is easy to insert and has the advantage of causing less sore throat and autonomic nervous system stimulation. To appropriately insert the LMA, an adequate depth of anesthesia is essential. Various drugs have been studied for inducing anesthesia to achieve the appropriate depth for LMA insertion, and the newly developed benzodiazepine, remimazolam, is gaining attention as one of them. Remimazolam has rapid onset and recovery times, hemodynamic stability, and is often co-administered with opioids like remifentanil for more effective LMA insertion. This study aims to find the optimal dose of remifentanil for the proper insertion of the Ambu Auragain, one of the recently developed LMAs, during induction of anesthesia using remimazolam and the Biased-Coin Up-and-Down method will be used for this purpose. Starting with an initial concentration of remifentanil of 3.0 μg/mL, the success or failure of LMA insertion will determine the dosage for the next subject. Data will be collected from a total of 60 patients, and subsequent analysis will be conducted., conditionsModule conditions: Adult, Laryngeal Masks, Remimazolam, Remifentanil, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 67, type: ESTIMATED, armsInterventionsModule interventions name: remifentanil of the assigned dose, interventions name: Ambu Auragain for airway management, outcomesModule primaryOutcomes measure: Success/failure of LMA insertion on the first attempt, secondaryOutcomes measure: Difficulty of LMA insertion, secondaryOutcomes measure: Optimality of the LMA insertion based on the administered remifentanil dose, secondaryOutcomes measure: The number of attempts required for successful LMA insertion and whether intubation was performed., secondaryOutcomes measure: Air leak volume during positive-pressure ventilation, secondaryOutcomes measure: Systolic blood pressure, secondaryOutcomes measure: Heart rate, secondaryOutcomes measure: Patient State Index (PSI), secondaryOutcomes measure: Severity of hoarseness, secondaryOutcomes measure: Severity of coughing, secondaryOutcomes measure: Severity of sore throat, secondaryOutcomes measure: Diastolic blood pressure, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: Severance Hospital, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Darhae Eum, Assistant Clinical Professor, role: CONTACT, phone: 82-2-2228-2431, email: deum@yuhs.ac, geoPoint lat: 37.566, lon: 126.9784, hasResults: False